NCT02650817View on ClinicalTrials.gov

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

August 30, 2018

Study Completion Date

October 18, 2019

Conditions

Metastatic Breast Cancer

Interventions

DRUG

RAD1901

RAD1901, a novel selective ER degrader (SERD)

Trial Locations (5)

1000

Institut Jules Bordet, Brussels

3000

UZ Leuven Campus Gasthuisberg, Leuven

Unknown

Vrije Universiteit Medisch Centrum (VUMC), Amsterdam

Universitair Medisch Centrum Groningen (UMCG), Groningen

Erasmus Medical Center, Rotterdam

All Listed Sponsors

lead

Stemline Therapeutics, Inc.

INDUSTRY

NCT02650817 - Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter